Comparison of risks and benefits of erythropoiesis-stimulating agents (ESAs) versus red blood cell (RBC) transfusion for chemotherapy-related anemia in patients with solid tumors

ESAs

RBC transfusion

Risks

Thrombotic events^*

Potentially decreased survival^*

Transfusion reactions^¶

Circulatory overload

Viral infection^Δ

Iron overload

Development of multiple alloantibodies

Benefits

Gradual improvement in hemoglobin/hematocrit

Gradual clinical improvement

Avoidance of RBC transfusions in some patients

Net reduction in transfusion requirements^◊

Rapid improvement in hemoglobin/hematocrit

Rapid clinical improvement

HIV: human immunodeficiency virus.
* In trials where target hemoglobin was >12 g/dL.
¶ Febrile nonhemolytic reactions (1:100); hemolytic reactions (1:19,000); transfusion-related acute lung injury (1:1000 to 1:5000).
Δ Hepatitis B, hepatitis C, HIV.
◊ Average 1 unit per person.

Graphic 78476 Version 5.0

خرید پکیج

Comparison of risks and benefits of erythropoiesis-stimulating agents (ESAs) versus red blood cell (RBC) transfusion for chemotherapy-related anemia in patients with solid tumors